AstraZeneca reports strong drug sales in Q2 amid lockdown
Newer drugs for diabetes, heart conditions and cancer, including its top selling lung cancer drug Tagrisso, performed well in the quarter and AstraZeneca remains on track for a third consecutive year of growth in sales.
UK: British drugmaker AstraZeneca topped second-quarter sales and profit estimates on Thursday and backed its 2020 forecasts, helped by strong sales in lockdowns of a diverse product range that now includes a potential coronavirus vaccine.Chief Executive Pascal Soriot has driven a change in the company's fortunes by investing in varied products and betting on newer medicines, which jolted...
Login or Register to read the full article
UK: British drugmaker AstraZeneca topped second-quarter sales and profit estimates on Thursday and backed its 2020 forecasts, helped by strong sales in lockdowns of a diverse product range that now includes a potential coronavirus vaccine.
Chief Executive Pascal Soriot has driven a change in the company's fortunes by investing in varied products and betting on newer medicines, which jolted the drugmaker onto the global stage.
Shares of Britain's most valuable listed company are seen rising 1-2% in London, according to a premarket indicator.
The company reiterated it was on track with late-stage trials for its coronavirus vaccine. "Our company has mounted a significant response to COVID-19, with capacity to deliver over two billion doses of AZD1222," Soriot said.
Product sales, which exclude payments from tie-ups, rose 9% to $6.05 billion in the three months ended June 30 on a constant-currency basis, surpassing analysts' consensus of $6.01 billion.
Newer drugs for diabetes, heart conditions and cancer, including its top selling lung cancer drug Tagrisso, performed well in the quarter and AstraZeneca remains on track for a third consecutive year of growth in sales.
Core earnings stood at 96 cents per share versus analysts' estimate of 93 cents. Total revenue rose 11%, AstraZeneca said.
Read also: EU talks with Pfizer, Sanofi, JnJ on Potential COVID Vaccines Struggle To Reach Deal: Report
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd